MoneyWorks4Me

Dr Reddy’s Laboratories launches Ropinirole Hydrochloride XR tablets

07 Jun 2012 Evaluate

Dr Reddy’s Laboratories has launched Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg), a bioequivalent generic version of REQUIP XL tablets in the US market, following United States Food & Drug Administration (USFDA’s) approval for Dr Reddy’s ANDA for Ropinirole Hydrochloride XR (Extended Release).

The REQUIP XL brand has US sales of approximately $58 million for the most recent twelve months ending March 2012 according to the IMS Health.

Dr Reddy’s Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg) are available in 30 and 90 count bottles sizes, 8 mg and 12 mg are available  in 30 count bottle sizes.

Dr. Reddys Labs. Share Price

1191.00 -3.50 (-0.29%)
25-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1917.00
Dr. Reddys Labs. 1191.00
Cipla 1420.00
Lupin 2175.00
Zydus Lifesciences 1130.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: